Safety and PK/PD of TG-0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients

NCT01018979 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

19

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma
Non-Hodgkin Lymphoma
Hodgkin Disease

Interventions

DRUG: TG-0054 (2.24 mg/kg)
DRUG: TG-0054 (3.14 mg/kg)

Sponsor

GPCR Therapeutics, Inc.